human cii Search Results


annexin v fitc pi staining  (MedChemExpress)
95
MedChemExpress annexin v fitc pi staining
Fig. 3. In vitro antitumor effect evaluation and mechanism exploration of M@GOx/Fe-HMON. (A–D) Intracellular glucose, NADPH, ATP, and cystine content in H22 cells treated with different formulations under low-glucose conditions. (E) Western blot analysis of GPX4 (ferroptosis marker), FLNA/B and MYH9 (disul fidptosis markers) in cells cultured under low- or high-glucose conditions. Vinculin was used as the loading control. (F) CLSM images showing F-actin integrity (red) in H22 cells incubated with various nanosamples under low-glucose conditions (scale bar = 100 μm). (G) Schematic illustration of the glucose-responsive activation of ferroptosis and disulfidptosis by M@GOx/Fe-HMON in glucose-rich and glucose-deficient TMEs. (H) FCM analysis of apoptosis <t>(Annexin</t> <t>V-FITC/PI)</t> under low- and high-glucose conditions, and quantification of apoptotic cell percentages. (I) Western blot analysis of P53, cleaved Caspase-3, Nrf2, and Keap1 in cells treated with M@GOx/Fe-HMON under different glucose conditions. **P < 0.01, *** P < 0.001, **** P < 0.0001; two-tailed t test; n = 3; mean ± SD.
Annexin V Fitc Pi Staining, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cii/Annexin+A5%2FANXA5%2C+Human/pm40253866-124-23-26
Average 95 stars, based on 1 article reviews
annexin v fitc pi staining - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
human sdhd  (OriGene)
90
OriGene human sdhd
Fig. 3. In vitro antitumor effect evaluation and mechanism exploration of M@GOx/Fe-HMON. (A–D) Intracellular glucose, NADPH, ATP, and cystine content in H22 cells treated with different formulations under low-glucose conditions. (E) Western blot analysis of GPX4 (ferroptosis marker), FLNA/B and MYH9 (disul fidptosis markers) in cells cultured under low- or high-glucose conditions. Vinculin was used as the loading control. (F) CLSM images showing F-actin integrity (red) in H22 cells incubated with various nanosamples under low-glucose conditions (scale bar = 100 μm). (G) Schematic illustration of the glucose-responsive activation of ferroptosis and disulfidptosis by M@GOx/Fe-HMON in glucose-rich and glucose-deficient TMEs. (H) FCM analysis of apoptosis <t>(Annexin</t> <t>V-FITC/PI)</t> under low- and high-glucose conditions, and quantification of apoptotic cell percentages. (I) Western blot analysis of P53, cleaved Caspase-3, Nrf2, and Keap1 in cells treated with M@GOx/Fe-HMON under different glucose conditions. **P < 0.01, *** P < 0.001, **** P < 0.0001; two-tailed t test; n = 3; mean ± SD.
Human Sdhd, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cii/SDHD+(NM_003002)+Human+Tagged+ORF+Clone/pm25417049-71-15-20
Average 90 stars, based on 1 article reviews
human sdhd - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
sdhd  (OriGene)
90
OriGene sdhd
Fig. 3. In vitro antitumor effect evaluation and mechanism exploration of M@GOx/Fe-HMON. (A–D) Intracellular glucose, NADPH, ATP, and cystine content in H22 cells treated with different formulations under low-glucose conditions. (E) Western blot analysis of GPX4 (ferroptosis marker), FLNA/B and MYH9 (disul fidptosis markers) in cells cultured under low- or high-glucose conditions. Vinculin was used as the loading control. (F) CLSM images showing F-actin integrity (red) in H22 cells incubated with various nanosamples under low-glucose conditions (scale bar = 100 μm). (G) Schematic illustration of the glucose-responsive activation of ferroptosis and disulfidptosis by M@GOx/Fe-HMON in glucose-rich and glucose-deficient TMEs. (H) FCM analysis of apoptosis <t>(Annexin</t> <t>V-FITC/PI)</t> under low- and high-glucose conditions, and quantification of apoptotic cell percentages. (I) Western blot analysis of P53, cleaved Caspase-3, Nrf2, and Keap1 in cells treated with M@GOx/Fe-HMON under different glucose conditions. **P < 0.01, *** P < 0.001, **** P < 0.0001; two-tailed t test; n = 3; mean ± SD.
Sdhd, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cii/SDHD+(NM_001276504)+Human+Untagged+Clone/pm31366990-294-6-9
Average 90 stars, based on 1 article reviews
sdhd - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
sdhd rescue clones  (OriGene)
90
OriGene sdhd rescue clones
Fig. 3. In vitro antitumor effect evaluation and mechanism exploration of M@GOx/Fe-HMON. (A–D) Intracellular glucose, NADPH, ATP, and cystine content in H22 cells treated with different formulations under low-glucose conditions. (E) Western blot analysis of GPX4 (ferroptosis marker), FLNA/B and MYH9 (disul fidptosis markers) in cells cultured under low- or high-glucose conditions. Vinculin was used as the loading control. (F) CLSM images showing F-actin integrity (red) in H22 cells incubated with various nanosamples under low-glucose conditions (scale bar = 100 μm). (G) Schematic illustration of the glucose-responsive activation of ferroptosis and disulfidptosis by M@GOx/Fe-HMON in glucose-rich and glucose-deficient TMEs. (H) FCM analysis of apoptosis <t>(Annexin</t> <t>V-FITC/PI)</t> under low- and high-glucose conditions, and quantification of apoptotic cell percentages. (I) Western blot analysis of P53, cleaved Caspase-3, Nrf2, and Keap1 in cells treated with M@GOx/Fe-HMON under different glucose conditions. **P < 0.01, *** P < 0.001, **** P < 0.0001; two-tailed t test; n = 3; mean ± SD.
Sdhd Rescue Clones, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cii/SDHD+(NM_003002)+Human+Untagged+Clone/10__1158_slash_0008___5472__can___20___2936-57-0-13
Average 90 stars, based on 1 article reviews
sdhd rescue clones - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
human cii purified from normal human cartilage  (MD Biosciences)
90
MD Biosciences human cii purified from normal human cartilage
Fig. 3. In vitro antitumor effect evaluation and mechanism exploration of M@GOx/Fe-HMON. (A–D) Intracellular glucose, NADPH, ATP, and cystine content in H22 cells treated with different formulations under low-glucose conditions. (E) Western blot analysis of GPX4 (ferroptosis marker), FLNA/B and MYH9 (disul fidptosis markers) in cells cultured under low- or high-glucose conditions. Vinculin was used as the loading control. (F) CLSM images showing F-actin integrity (red) in H22 cells incubated with various nanosamples under low-glucose conditions (scale bar = 100 μm). (G) Schematic illustration of the glucose-responsive activation of ferroptosis and disulfidptosis by M@GOx/Fe-HMON in glucose-rich and glucose-deficient TMEs. (H) FCM analysis of apoptosis <t>(Annexin</t> <t>V-FITC/PI)</t> under low- and high-glucose conditions, and quantification of apoptotic cell percentages. (I) Western blot analysis of P53, cleaved Caspase-3, Nrf2, and Keap1 in cells treated with M@GOx/Fe-HMON under different glucose conditions. **P < 0.01, *** P < 0.001, **** P < 0.0001; two-tailed t test; n = 3; mean ± SD.
Human Cii Purified From Normal Human Cartilage, supplied by MD Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cii/human+cii+purified+from+normal+human+cartilage/pmc01779380-21-5-10
Average 90 stars, based on 1 article reviews
human cii purified from normal human cartilage - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
antigens human cii  (MD Biosciences)
90
MD Biosciences antigens human cii
Fig. 3. In vitro antitumor effect evaluation and mechanism exploration of M@GOx/Fe-HMON. (A–D) Intracellular glucose, NADPH, ATP, and cystine content in H22 cells treated with different formulations under low-glucose conditions. (E) Western blot analysis of GPX4 (ferroptosis marker), FLNA/B and MYH9 (disul fidptosis markers) in cells cultured under low- or high-glucose conditions. Vinculin was used as the loading control. (F) CLSM images showing F-actin integrity (red) in H22 cells incubated with various nanosamples under low-glucose conditions (scale bar = 100 μm). (G) Schematic illustration of the glucose-responsive activation of ferroptosis and disulfidptosis by M@GOx/Fe-HMON in glucose-rich and glucose-deficient TMEs. (H) FCM analysis of apoptosis <t>(Annexin</t> <t>V-FITC/PI)</t> under low- and high-glucose conditions, and quantification of apoptotic cell percentages. (I) Western blot analysis of P53, cleaved Caspase-3, Nrf2, and Keap1 in cells treated with M@GOx/Fe-HMON under different glucose conditions. **P < 0.01, *** P < 0.001, **** P < 0.0001; two-tailed t test; n = 3; mean ± SD.
Antigens Human Cii, supplied by MD Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cii/antigens+human+cii/pmc01954639-34-0-6
Average 90 stars, based on 1 article reviews
antigens human cii - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
type ii human collagen (cii)259–263 peptide (giagfkgeqgpkget)  (GenScript corporation)
90
GenScript corporation type ii human collagen (cii)259–263 peptide (giagfkgeqgpkget)
Fig. 3. In vitro antitumor effect evaluation and mechanism exploration of M@GOx/Fe-HMON. (A–D) Intracellular glucose, NADPH, ATP, and cystine content in H22 cells treated with different formulations under low-glucose conditions. (E) Western blot analysis of GPX4 (ferroptosis marker), FLNA/B and MYH9 (disul fidptosis markers) in cells cultured under low- or high-glucose conditions. Vinculin was used as the loading control. (F) CLSM images showing F-actin integrity (red) in H22 cells incubated with various nanosamples under low-glucose conditions (scale bar = 100 μm). (G) Schematic illustration of the glucose-responsive activation of ferroptosis and disulfidptosis by M@GOx/Fe-HMON in glucose-rich and glucose-deficient TMEs. (H) FCM analysis of apoptosis <t>(Annexin</t> <t>V-FITC/PI)</t> under low- and high-glucose conditions, and quantification of apoptotic cell percentages. (I) Western blot analysis of P53, cleaved Caspase-3, Nrf2, and Keap1 in cells treated with M@GOx/Fe-HMON under different glucose conditions. **P < 0.01, *** P < 0.001, **** P < 0.0001; two-tailed t test; n = 3; mean ± SD.
Type Ii Human Collagen (Cii)259–263 Peptide (Giagfkgeqgpkget), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cii/type+ii+human+collagen++cii+259+263+peptide++giagfkgeqgpkget+/pm24465795-88-0-7
Average 90 stars, based on 1 article reviews
type ii human collagen (cii)259–263 peptide (giagfkgeqgpkget) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
human cii  (MD Biosciences)
90
MD Biosciences human cii
Fig. 3. In vitro antitumor effect evaluation and mechanism exploration of M@GOx/Fe-HMON. (A–D) Intracellular glucose, NADPH, ATP, and cystine content in H22 cells treated with different formulations under low-glucose conditions. (E) Western blot analysis of GPX4 (ferroptosis marker), FLNA/B and MYH9 (disul fidptosis markers) in cells cultured under low- or high-glucose conditions. Vinculin was used as the loading control. (F) CLSM images showing F-actin integrity (red) in H22 cells incubated with various nanosamples under low-glucose conditions (scale bar = 100 μm). (G) Schematic illustration of the glucose-responsive activation of ferroptosis and disulfidptosis by M@GOx/Fe-HMON in glucose-rich and glucose-deficient TMEs. (H) FCM analysis of apoptosis <t>(Annexin</t> <t>V-FITC/PI)</t> under low- and high-glucose conditions, and quantification of apoptotic cell percentages. (I) Western blot analysis of P53, cleaved Caspase-3, Nrf2, and Keap1 in cells treated with M@GOx/Fe-HMON under different glucose conditions. **P < 0.01, *** P < 0.001, **** P < 0.0001; two-tailed t test; n = 3; mean ± SD.
Human Cii, supplied by MD Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cii/human+cii/pmc01954639-66-0-5
Average 90 stars, based on 1 article reviews
human cii - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
human annexin v elisa kit  (Shanghai Korain Biotech Co Ltd)
94
Shanghai Korain Biotech Co Ltd human annexin v elisa kit
Fig. 3. In vitro antitumor effect evaluation and mechanism exploration of M@GOx/Fe-HMON. (A–D) Intracellular glucose, NADPH, ATP, and cystine content in H22 cells treated with different formulations under low-glucose conditions. (E) Western blot analysis of GPX4 (ferroptosis marker), FLNA/B and MYH9 (disul fidptosis markers) in cells cultured under low- or high-glucose conditions. Vinculin was used as the loading control. (F) CLSM images showing F-actin integrity (red) in H22 cells incubated with various nanosamples under low-glucose conditions (scale bar = 100 μm). (G) Schematic illustration of the glucose-responsive activation of ferroptosis and disulfidptosis by M@GOx/Fe-HMON in glucose-rich and glucose-deficient TMEs. (H) FCM analysis of apoptosis <t>(Annexin</t> <t>V-FITC/PI)</t> under low- and high-glucose conditions, and quantification of apoptotic cell percentages. (I) Western blot analysis of P53, cleaved Caspase-3, Nrf2, and Keap1 in cells treated with M@GOx/Fe-HMON under different glucose conditions. **P < 0.01, *** P < 0.001, **** P < 0.0001; two-tailed t test; n = 3; mean ± SD.
Human Annexin V Elisa Kit, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cii/Human+Annexin+5/10__1016_slash_j__genrep__2025__102413-97-6-11
Average 94 stars, based on 1 article reviews
human annexin v elisa kit - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
apolipoprotein cii (apoc2) (nm_000483) human recombinant protein  (OriGene)
90
OriGene apolipoprotein cii (apoc2) (nm_000483) human recombinant protein
Fig. 3. In vitro antitumor effect evaluation and mechanism exploration of M@GOx/Fe-HMON. (A–D) Intracellular glucose, NADPH, ATP, and cystine content in H22 cells treated with different formulations under low-glucose conditions. (E) Western blot analysis of GPX4 (ferroptosis marker), FLNA/B and MYH9 (disul fidptosis markers) in cells cultured under low- or high-glucose conditions. Vinculin was used as the loading control. (F) CLSM images showing F-actin integrity (red) in H22 cells incubated with various nanosamples under low-glucose conditions (scale bar = 100 μm). (G) Schematic illustration of the glucose-responsive activation of ferroptosis and disulfidptosis by M@GOx/Fe-HMON in glucose-rich and glucose-deficient TMEs. (H) FCM analysis of apoptosis <t>(Annexin</t> <t>V-FITC/PI)</t> under low- and high-glucose conditions, and quantification of apoptotic cell percentages. (I) Western blot analysis of P53, cleaved Caspase-3, Nrf2, and Keap1 in cells treated with M@GOx/Fe-HMON under different glucose conditions. **P < 0.01, *** P < 0.001, **** P < 0.0001; two-tailed t test; n = 3; mean ± SD.
Apolipoprotein Cii (Apoc2) (Nm 000483) Human Recombinant Protein, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cii/Apolipoprotein+CII+(APOC2)+(NM_000483)+Human+Recombinant+Protein/origene___tp302771
Average 90 stars, based on 1 article reviews
apolipoprotein cii (apoc2) (nm_000483) human recombinant protein - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
apolipoprotein cii apoc2 nm 000483 human tagged orf clone lentiviral particle  (OriGene)
N/A
Lenti ORF particles APOC2 Myc DDK tagged Human apolipoprotein C II APOC2 200ul 10 7 TU mL
   Buy from Supplier

Image Search Results


Fig. 3. In vitro antitumor effect evaluation and mechanism exploration of M@GOx/Fe-HMON. (A–D) Intracellular glucose, NADPH, ATP, and cystine content in H22 cells treated with different formulations under low-glucose conditions. (E) Western blot analysis of GPX4 (ferroptosis marker), FLNA/B and MYH9 (disul fidptosis markers) in cells cultured under low- or high-glucose conditions. Vinculin was used as the loading control. (F) CLSM images showing F-actin integrity (red) in H22 cells incubated with various nanosamples under low-glucose conditions (scale bar = 100 μm). (G) Schematic illustration of the glucose-responsive activation of ferroptosis and disulfidptosis by M@GOx/Fe-HMON in glucose-rich and glucose-deficient TMEs. (H) FCM analysis of apoptosis (Annexin V-FITC/PI) under low- and high-glucose conditions, and quantification of apoptotic cell percentages. (I) Western blot analysis of P53, cleaved Caspase-3, Nrf2, and Keap1 in cells treated with M@GOx/Fe-HMON under different glucose conditions. **P < 0.01, *** P < 0.001, **** P < 0.0001; two-tailed t test; n = 3; mean ± SD.

Journal: Journal of colloid and interface science

Article Title: Redox-driven hybrid nanoenzyme dynamically activating ferroptosis and disulfidptosis for hepatocellular carcinoma theranostics.

doi: 10.1016/j.jcis.2025.137611

Figure Lengend Snippet: Fig. 3. In vitro antitumor effect evaluation and mechanism exploration of M@GOx/Fe-HMON. (A–D) Intracellular glucose, NADPH, ATP, and cystine content in H22 cells treated with different formulations under low-glucose conditions. (E) Western blot analysis of GPX4 (ferroptosis marker), FLNA/B and MYH9 (disul fidptosis markers) in cells cultured under low- or high-glucose conditions. Vinculin was used as the loading control. (F) CLSM images showing F-actin integrity (red) in H22 cells incubated with various nanosamples under low-glucose conditions (scale bar = 100 μm). (G) Schematic illustration of the glucose-responsive activation of ferroptosis and disulfidptosis by M@GOx/Fe-HMON in glucose-rich and glucose-deficient TMEs. (H) FCM analysis of apoptosis (Annexin V-FITC/PI) under low- and high-glucose conditions, and quantification of apoptotic cell percentages. (I) Western blot analysis of P53, cleaved Caspase-3, Nrf2, and Keap1 in cells treated with M@GOx/Fe-HMON under different glucose conditions. **P < 0.01, *** P < 0.001, **** P < 0.0001; two-tailed t test; n = 3; mean ± SD.

Article Snippet: For apoptosis analysis, cells were treated under high-glucose conditions for 12 h or low-glucose conditions for 4 h with various formulations, followed by Annexin V-FITC/PI staining (MCE, USA) and FCM.

Techniques: In Vitro, Western Blot, Marker, Cell Culture, Control, Incubation, Activation Assay, Two Tailed Test